Thursday, September 19, 2019 7:15:31 AM
GC Announces IRB Approval of its IGC-AD1 for a Phase-2 study
Business Wire Business Wire•September 19, 2019
BETHESDA, Md.--(BUSINESS WIRE)--
India Globalization Capital, Inc. (IGC) announced today that the Institutional Review Board (“IRB”), in Puerto Rico, approved its protocol for a double-blind, placebo-controlled, efficacy, safety and tolerability study of its proprietary formulation IGC-AD1 on behavior and functionality in subjects with dementia from Alzheimer’s disease.
“With this important approval, our Company can implement a 50-person double-blind placebo-controlled trial that we hope begins to prove the efficacy of micro-doses of cannabis in combination with other natural compounds on the behavior of patients suffering from Alzheimer’s. We expect to measure improvements in neuropsychiatric symptoms (“NPI”) such as delusions, agitation/aggression, dysphoria, anxiety, sleep disorder, disinhibition, irritability, apathy and eating abnormalities, among others,” stated Ram Mukunda, CEO.
In 2017, IGC acquired a patent filing from the University of South Florida (USF) that showed that micro-doses of cannabis in combination with other natural compounds are beneficial to Alzheimer’s cell lines and to memory in transgenic mice. Our product Hyalolex™, modeled after IGC-AD1 and currently available in more than 40 dispensaries in Puerto Rico is based on this research.
Regarding the IRB approval for a Phase-2 study, Mr. Mukunda added, “Our Company will now prepare and file an Investigational New Drug Application (”INDA”) with the FDA in support of the protocol. Given that there is no cure or effective treatment for Alzheimer’s we are hopeful that the FDA will grant the INDA, but there can be no guarantee”. The University of Puerto Rico Medical Sciences Campus maintains IRB panels that is responsible for approving research protocols on human subjects.
About IGC
IGC has two lines of business: i) infrastructure and ii) plant and cannabinoid-based products. The company is based in Maryland, U.S.A. Our websites: www.igcinc.us; www.igcpharma.com; Twitter @IGCIR.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on IGC’s expectations and are subject to a number of risks and uncertainties, certain of which are beyond IGC’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, competitive conditions in the industries in which IGC operates, the results and implementation of the Phase-2 study, failure to commercialize one or more of the technologies of IGC, general economic conditions that are less favorable than expected, the Federal Food and Drug Administration’s (FDA) general position regarding cannabis-based products and our products in particular, and other factors, many of which are discussed in our SEC filings. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this press release will in fact occur.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190919005241/en/
Recent IGC News
- IGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week Two • Business Wire • 04/16/2024 11:00:00 AM
- IGC Pharma Adds Advisor in Artificial Intelligence • Business Wire • 04/09/2024 01:00:00 PM
- IGC Pharma Announces $3 Million Unregistered Private Placement of its Common Stock • Business Wire • 03/26/2024 07:00:00 PM
- IGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation • Business Wire • 03/20/2024 03:00:00 PM
- IGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024 • Business Wire • 03/20/2024 11:00:00 AM
- IGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s Pipeline • Business Wire • 03/12/2024 07:00:00 PM
- Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model • Business Wire • 02/28/2024 06:00:00 PM
- IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target • Business Wire • 02/23/2024 05:01:00 PM
- IGC Pharma Reports Third Quarter Fiscal 2024 Results • Business Wire • 02/17/2024 12:05:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:03:00 PM
- IGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse Model • Business Wire • 02/01/2024 02:20:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/31/2024 09:04:23 PM
- IGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’s • Business Wire • 01/23/2024 02:20:00 PM
- IGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s Trial • Business Wire • 01/17/2024 02:20:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/09/2024 05:15:07 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/29/2023 09:54:29 PM
- Patent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’s • Business Wire • 12/19/2023 02:20:00 PM
- IGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024 • Business Wire • 12/13/2023 02:30:00 PM
- IGC Pharma Announces Collaboration to Integrate AI into Clinical Trials • Business Wire • 12/06/2023 01:30:00 PM
- IGC Pharma Announces Master Agreement with Leading South American University to Advance AI Initiatives • Business Wire • 11/21/2023 01:30:00 PM
- IGC Pharma Reports Second Quarter Fiscal 2024 Results • Business Wire • 11/13/2023 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:15:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 09:21:48 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/27/2023 08:38:17 PM
- IGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief Therapy • Business Wire • 10/19/2023 07:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM